Joana Marinho: Avelumab Maintenance Therapy in Advanced Urothelial Carcinoma
Joana Marinho, Head of the Oncology Day Hospital Medical Department at Gaia and Espinho Local Health Unit, posted on LinkedIn about recent paper by Lisa Gonçalves et al., titled “Avelumab Maintenance Therapy in Advanced Urothelial Carcinoma: Implications of Timing and Treatment Sequencing” published on MDPI.
Authors: Lisa Gonçalves, Helena Guedes, Ana Raquel Fortuna, Tânia Lemos, João Gramaça, Natacha Mourão, Gonçalo Cunha, Rita Pichel, Pedro Simões, Joana Alves Luís, Rita Freitas, Inês Dunões, Ana Sofia Spencer, Joana Marinho, Luís Costa
“Congratulations to the collaborative, Portuguese multicentric team behind the publication:
Avelumab Maintenance Therapy in Advanced Urothelial Carcinoma: Implications of Timing and Treatment Sequencing.
This important real-world study, conducted across multiple centers in Portugal, evaluated the safety and efficacy of avelumab maintenance therapy in patients with advanced urothelial carcinoma (aUC).
Key Findings:
- Median progression-free survival (PFS): 9.8 months.
- Median overall survival (OS): 39.5 months, exceeding outcomes from the pivotal JAVELIN Bladder 100 trial.
- Immune-related adverse events (irAEs) occurred in 65.8% of patients, with 6.7% experiencing Grade 3 irAEs.
Morning avelumab infusions were associated with significantly improved overall survival (HR 0.35, p = 0.042).
This study not only confirms the effectiveness of avelumab in real-world practice but also highlights the potential impact of treatment timing on patient outcomes!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023